- Home
- RRC vs HALO Comparison
RRC vs HALO Comparison
Compare RRC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RRC | HALO |
|---|---|---|
| Founded | 1976 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RRC | HALO |
|---|---|---|
| Price | $35.89 | $71.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $41.61 | ★ $76.42 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 02-24-2026 | 02-17-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | 19.84 | ★ 56.68 |
| EPS | 2.38 | ★ 4.74 |
| Revenue | ★ $2,891,506,000.00 | $1,242,852,000.00 |
| Revenue This Year | $27.23 | $34.54 |
| Revenue Next Year | $11.85 | $26.28 |
| P/E Ratio | $15.25 | ★ $15.14 |
| Revenue Growth | 24.57 | ★ 31.19 |
| 52 Week Low | $30.32 | $47.50 |
| 52 Week High | $43.50 | $79.50 |
Technical Indicators
Market Signals| Indicator | RRC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 54.57 |
| Support Level | $32.68 | $69.53 |
| Resistance Level | $37.11 | $72.33 |
| Average True Range (ATR) | 1.10 | 2.14 |
| MACD | 0.30 | -0.15 |
| Stochastic Oscillator | 73.14 | 49.70 |
Price Performance
Historical ComparisonAbout RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.2 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.